JP2024515555A5 - - Google Patents
Info
- Publication number
- JP2024515555A5 JP2024515555A5 JP2023561628A JP2023561628A JP2024515555A5 JP 2024515555 A5 JP2024515555 A5 JP 2024515555A5 JP 2023561628 A JP2023561628 A JP 2023561628A JP 2023561628 A JP2023561628 A JP 2023561628A JP 2024515555 A5 JP2024515555 A5 JP 2024515555A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation according
- pharmaceutical product
- formulation
- present
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163171429P | 2021-04-06 | 2021-04-06 | |
| US63/171,429 | 2021-04-06 | ||
| PCT/US2022/071562 WO2022217231A1 (en) | 2021-04-06 | 2022-04-05 | Formulations of l-asparaginase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024515555A JP2024515555A (ja) | 2024-04-10 |
| JP2024515555A5 true JP2024515555A5 (enExample) | 2025-04-14 |
Family
ID=81748398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023561628A Pending JP2024515555A (ja) | 2021-04-06 | 2022-04-05 | Ｌ－アスパラギナーゼの製剤 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP4319818A1 (enExample) |
| JP (1) | JP2024515555A (enExample) |
| KR (1) | KR20230165799A (enExample) |
| CN (1) | CN117377494A (enExample) |
| AR (1) | AR125301A1 (enExample) |
| AU (1) | AU2022256071A1 (enExample) |
| BR (1) | BR112023019862A2 (enExample) |
| CA (1) | CA3213726A1 (enExample) |
| CL (1) | CL2023002983A1 (enExample) |
| CO (1) | CO2023014093A2 (enExample) |
| MX (1) | MX2023011693A (enExample) |
| WO (1) | WO2022217231A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022211829A1 (en) | 2021-03-30 | 2022-10-06 | Jazz Pharmaceuticals Ireland Ltd. | Dosing of recombinant l-asparaginase |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7985548B2 (en) | 2006-03-03 | 2011-07-26 | The United States Of America As Represented By The Department Of Health And Human Services | Materials and methods directed to asparagine synthetase and asparaginase therapies |
| CN109640961B (zh) * | 2016-06-01 | 2021-11-02 | 施维雅知识产权英国有限公司 | 聚亚烷基氧化物-天冬酰胺酶制剂及其制备和使用方法 |
| CA3240356A1 (en) * | 2017-11-30 | 2019-06-06 | Jazz Pharmaceuticals Ireland Ltd. | Methods of treatment with asparaginase |
| CA3156066A1 (en) * | 2019-10-25 | 2021-04-29 | Mi Rim Choi | Recombinant l-asparaginase |
-
2022
- 2022-04-05 MX MX2023011693A patent/MX2023011693A/es unknown
- 2022-04-05 KR KR1020237037007A patent/KR20230165799A/ko active Pending
- 2022-04-05 AR ARP220100846A patent/AR125301A1/es unknown
- 2022-04-05 EP EP22724215.3A patent/EP4319818A1/en active Pending
- 2022-04-05 WO PCT/US2022/071562 patent/WO2022217231A1/en not_active Ceased
- 2022-04-05 CN CN202280032191.2A patent/CN117377494A/zh active Pending
- 2022-04-05 AU AU2022256071A patent/AU2022256071A1/en active Pending
- 2022-04-05 BR BR112023019862A patent/BR112023019862A2/pt unknown
- 2022-04-05 CA CA3213726A patent/CA3213726A1/en active Pending
- 2022-04-05 JP JP2023561628A patent/JP2024515555A/ja active Pending
-
2023
- 2023-10-05 CL CL2023002983A patent/CL2023002983A1/es unknown
- 2023-10-23 CO CONC2023/0014093A patent/CO2023014093A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230047111A1 (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
| JP2024503265A5 (enExample) | ||
| FI4267105T3 (fi) | Vasta-ainekoostumuksia ja niiden käyttömenetelmiä | |
| JP7175506B2 (ja) | 低血圧治療のための単独または併用使用されるアンギオテンシンｉｉ | |
| JP2002544174A5 (enExample) | ||
| JP2010511665A5 (enExample) | ||
| FI3990005T3 (fi) | Pegyloitu kystationiini-beta-syntaasi entsyymihoitoa varten homokystinurian hoitamiseksi | |
| JP2022539077A5 (enExample) | ||
| JP2024515555A5 (enExample) | ||
| JP2011506436A (ja) | 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 | |
| US12564619B2 (en) | Stable formulations of recombinant proteins | |
| JPH0618781B2 (ja) | 感染症治療剤 | |
| US11554156B2 (en) | Pharmaceutical formulations of C1 esterase inhibitor | |
| RU2690677C1 (ru) | Стабилизированная композиция, обладающая противовирусной, противоопухолевой, иммуномодулирующей, актопротекторной, антимутагенной и антиоксидантной активностью | |
| IL312401A (en) | Methods of treating crohn's disease with anti-il23 specific antibody | |
| CN111432821A (zh) | 治疗细菌感染的方法 | |
| JP2770911B2 (ja) | 抗ウイルス医薬組成物 | |
| RU2220730C2 (ru) | Способ лечения герпетического стоматита | |
| WO2021162525A1 (ko) | 히드록시유레아를 포함하는 염증 반응 억제용 약학 조성물 | |
| US20210386736A1 (en) | Combination therapy for treating cancer | |
| JP3022915B2 (ja) | 癌転移抑制剤 | |
| WO2022161554A4 (es) | Composición farmacéutica que comprende el ghrp-6 | |
| EP1488800A1 (en) | Agent for the treatment of protozoal diseases | |
| JP7417339B1 (ja) | アデノウイルス感染又はアデノウイルス感染に伴う疾患の治療 | |
| ES2862462B2 (es) | Compuestos para la profilaxis y/o el tratamiento del sindrome de dificultad respiratoria aguda |